Eclipse Life Sciences

Eclipse Life Sciences is a private, US-based CDMO that has positioned itself in the high-growth sterile injectables market, with a specific focus on complex biosimilars and small molecules. The company leverages its expertise in aseptic processing to offer a critical service to biopharma companies, aiming to reduce development timelines and mitigate manufacturing risks for its clients. Operating from a strategic location in the Research Triangle, it targets a market driven by patent expiries and demand for cost-effective biologics. As a service provider, its financial success is tied to its ability to secure and execute on client contracts, competing with larger, established CDMOs.

Specialized contract development and manufacturing (CDMO) platform for sterile injectable pharmaceuticals, encompassing formulation development, analytical services, and aseptic fill-finish capabilities for biosimilars and small molecules.

Eclipse competes in the fragmented but competitive CDMO market for sterile injectables. Major players include global giants like Catalent, Lonza, and Baxter, as well as specialized firms like Pfizer CentreOne and Viatris. Differentiation is achieved through niche expertise, technological capabilities, quality reputation, and customer service.